Last reviewed · How we verify

Metformin (open-label) — Competitive Intelligence Brief

Metformin (open-label) (Metformin (open-label)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Biguanide. Area: Diabetes.

phase 3 Biguanide AMP-activated protein kinase (AMPK); mitochondrial complex I Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Metformin (open-label) (Metformin (open-label)) — Medical College of Wisconsin. Metformin reduces hepatic glucose production and improves insulin sensitivity by activating AMP-activated protein kinase (AMPK) and inhibiting mitochondrial complex I.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Metformin (open-label) TARGET Metformin (open-label) Medical College of Wisconsin phase 3 Biguanide AMP-activated protein kinase (AMPK); mitochondrial complex I
Pioglitazone and Metformin Pioglitazone and Metformin Takeda marketed Thiazolidinedione + Biguanide combination PPAR-γ (pioglitazone); Complex I of mitochondrial respiratory chain (metformin)
Placebo plus metformin Placebo plus metformin University Magna Graecia marketed Biguanide AMP-activated protein kinase (AMPK), mitochondrial glycerophosphate dehydrogenase
MET + Glibenclamide Group MET + Glibenclamide Group Hospital de Clinicas de Porto Alegre marketed Antidiabetic combination (biguanide + sulfonylurea) AMPK pathway (metformin); ATP-sensitive potassium channel (glibenclamide)
Pioglitazone vs Metformin Pioglitazone vs Metformin Post Graduate Institute of Medical Education and Research, Chandigarh marketed Antidiabetic agents (thiazolidinedione vs. biguanide) Pioglitazone: PPAR-γ; Metformin: AMPK
Met IR Met IR Elcelyx Therapeutics, Inc. marketed Biguanide AMP-activated protein kinase (AMPK)
Metformin + Clomiphene Metformin + Clomiphene University of Auckland, New Zealand marketed Combination therapy: biguanide + selective estrogen receptor modulator (SERM) Metformin: AMP-activated protein kinase (AMPK); Clomiphene: estrogen receptor (ER)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Biguanide class)

  1. AstraZeneca · 4 drugs in this class
  2. Merck Sharp & Dohme LLC · 3 drugs in this class
  3. University of Texas Southwestern Medical Center · 2 drugs in this class
  4. Mount Sinai Hospital, Canada · 2 drugs in this class
  5. GlaxoSmithKline · 2 drugs in this class
  6. Eli Lilly and Company · 2 drugs in this class
  7. University Magna Graecia · 2 drugs in this class
  8. First Affiliated Hospital of Wenzhou Medical University · 1 drug in this class
  9. Ente Ospedaliero Ospedali Galliera · 1 drug in this class
  10. Daewoong Pharmaceutical Co. LTD. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Metformin (open-label) — Competitive Intelligence Brief. https://druglandscape.com/ci/metformin-open-label. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: